Kabra Drugs Ltd

Kabra Drugs Ltd

Kabra Drugs Ltd has reconstituted its Board of Directors and Committees as per Regulation 30 of SEBI (LODR) Regulations, 2015, effective from August 12, 2026. The new composition includes Nanjappan Aravind as Executive Director, Managing Director, and Chairperson, and four independent directors: Nikita Sinha, Ritu Tiwari, Moonam Kapoor, and Kuniamuthur Nanjappan Anand.

Kabra Drugs Ltd

Kabra Drugs Ltd has published an unaudited financial results for the quarter ended on 30th June 2026 in a newspaper advertisement.

Kabra Drugs Ltd

Kabra Drugs Ltd announced the resignation of Ms. Anand Anitha as Director of the Company, effective August 12, 2026, citing personal reasons.

Kabra Drugs Ltd

Kabra Drugs Ltd, now known as Aanjaay Industries Ltd, has submitted an undertaking to the BSE stating that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company for the quarter ended 30th June 2026. The company has not issued any shares through public issue, rights issue, or preferential issue during this period.

Kabra Drugs Ltd

Kabra Drugs Ltd (formerly known as Kabra Drugs Limited) has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a net profit of ₹212.30 lakhs, with revenue from operations at ₹4621.68 lakhs and total income at ₹4629.33 lakhs.

Kabra Drugs Ltd

Kabra Drugs Ltd (formerly known as Kabra Drugs Limited) has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a net profit of ₹212.30 lakhs, with earnings per share (EPS) of ₹0.90. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 12th, 2026.

Kabra Drugs Ltd

Kabra Drugs Ltd has scheduled a Board Meeting on 12-Aug-2026 to consider unaudited financial results for Q2 FY2026-27, resignation of a director, and other business.